These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 21235422)

  • 21. Effect of cholesteryl ester transfer protein inhibitor on vitamin E transport should be studied.
    Masterjohn C
    Am Heart J; 2009 Jul; 158(1):e11; author reply e13. PubMed ID: 19540377
    [No Abstract]   [Full Text] [Related]  

  • 22. Novel cholesteryl ester transfer protein inhibitors: promising therapy for dyslipidemia?
    Devaraj S; Jialal I
    Metab Syndr Relat Disord; 2011 Jun; 9(3):163-5. PubMed ID: 21557663
    [No Abstract]   [Full Text] [Related]  

  • 23. Design and synthesis of potent inhibitors of cholesteryl ester transfer protein (CETP) exploiting a 1,2,3,4-tetrahydroquinoline platform.
    Rano TA; Sieber-McMaster E; Pelton PD; Yang M; Demarest KT; Kuo GH
    Bioorg Med Chem Lett; 2009 May; 19(9):2456-60. PubMed ID: 19339179
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CETP inhibitor torcetrapib promotes reverse cholesterol transport in obese insulin-resistant CETP-ApoB100 transgenic mice.
    Briand F; Thieblemont Q; André A; Ouguerram K; Sulpice T
    Clin Transl Sci; 2011 Dec; 4(6):414-20. PubMed ID: 22212222
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Good news for 'good' cholesterol.
    Katsnelson A
    Nature; 2010 Nov; 468(7322):354. PubMed ID: 21085143
    [No Abstract]   [Full Text] [Related]  

  • 26. Increasing high-density lipoprotein cholesterol, inhibition of cholesteryl ester transfer protein, and heart disease risk reduction.
    Schaefer EJ; Asztalos BF
    Am J Cardiol; 2007 Dec; 100(11 A):n25-31. PubMed ID: 18047849
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Is a blood pressure rise the only deleterious off-target effect of cholesterol ester transfer protein inhibitors?
    Miura S; Saku K
    J Hypertens; 2010 Aug; 28(8):1614-6. PubMed ID: 20647856
    [No Abstract]   [Full Text] [Related]  

  • 28. Anacetrapib: a new weapon against dyslipidemia.
    Aperis G; Paliouras C; Tsampikaki E; Papakonstantinou N; Alivanis P
    Curr Clin Pharmacol; 2011 Nov; 6(4):227-35. PubMed ID: 22082322
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of CP-532,623 and torcetrapib, cholesteryl ester transfer protein inhibitors, on arterial blood pressure.
    Blasi E; Bamberger M; Knight D; Engwall M; Wolk R; Winter S; Betts A; John-Baptiste A; Keiser J
    J Cardiovasc Pharmacol; 2009 Jun; 53(6):507-16. PubMed ID: 19455053
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HDL: back to the drawing board.
    Johns Hopkins Med Lett Health After 50; 2007 May; 19(3):1-2. PubMed ID: 17657883
    [No Abstract]   [Full Text] [Related]  

  • 31. Anacetrapib.
    Am J Cardiovasc Drugs; 2010; 10(4):267-70. PubMed ID: 20653333
    [TBL] [Abstract][Full Text] [Related]  

  • 32. When good cholesterol turns bad: the evolving saga of CETP inhibitors and clinical strategies to elevate high-density lipoprotein.
    Oram JF; Heinecke JW
    Curr Atheroscler Rep; 2007 Dec; 9(6):425-7. PubMed ID: 18377780
    [No Abstract]   [Full Text] [Related]  

  • 33. Unending saga of fighting cholesterol: Evacetrapib is another fallen warrior.
    Simko V
    Bratisl Lek Listy; 2016; 117(11):625-627. PubMed ID: 28125886
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Increasing high-density lipoprotein cholesterol by cholesteryl ester transfer protein-inhibition: a rocky road and lessons learned? The early demise of the dal-HEART programme.
    Landmesser U; von Eckardstein A; Kastelein J; Deanfield J; Lüscher TF
    Eur Heart J; 2012 Jul; 33(14):1712-5. PubMed ID: 22696435
    [No Abstract]   [Full Text] [Related]  

  • 35. Dyslipidaemia: Revealing the effect of CETP inhibition in cardiovascular disease.
    Holmes MV; Smith GD
    Nat Rev Cardiol; 2017 Nov; 14(11):635-636. PubMed ID: 28980665
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of cholesteryl ester transfer protein by torcetrapib modestly increases macrophage cholesterol efflux to HDL.
    Yvan-Charvet L; Matsuura F; Wang N; Bamberger MJ; Nguyen T; Rinninger F; Jiang XC; Shear CL; Tall AR
    Arterioscler Thromb Vasc Biol; 2007 May; 27(5):1132-8. PubMed ID: 17322101
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The hypertension peril: lessons from CETP inhibitors.
    Hermann M; Ruschitzka FT
    Curr Hypertens Rep; 2009 Feb; 11(1):76-80. PubMed ID: 19146805
    [TBL] [Abstract][Full Text] [Related]  

  • 38. SAR studies on the central phenyl ring of substituted biphenyl oxazolidinone-potent CETP inhibitors.
    Lu Z; Chen YH; Napolitano JB; Taylor G; Ali A; Hammond ML; Deng Q; Tan E; Tong X; Xu SS; Latham MJ; Peterson LB; Anderson MS; Eveland SS; Guo Q; Hyland SA; Milot DP; Chen Y; Sparrow CP; Wright SD; Sinclair PJ
    Bioorg Med Chem Lett; 2012 Jan; 22(1):199-203. PubMed ID: 22142541
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol.
    Brousseau ME; Schaefer EJ; Wolfe ML; Bloedon LT; Digenio AG; Clark RW; Mancuso JP; Rader DJ
    N Engl J Med; 2004 Apr; 350(15):1505-15. PubMed ID: 15071125
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mechanism of inhibition defines CETP activity: a mathematical model for CETP in vitro.
    Potter LK; Sprecher DL; Walker MC; Tobin FL
    J Lipid Res; 2009 Nov; 50(11):2222-34. PubMed ID: 19282272
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.